A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors.Anthony W. Tolcher, Sergio Santillana, Laura Victor et al.|Journal of Clinical Oncology|2022Cited by 49
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trialRolando Pajón, F. Schödel, Yamuna Devi Paila et al.|Nature Medicine|2022Cited by 36